Dealing Room Buzz: SBI, Sterlite Tech, Mankind Pharma, Godrej Properties, Hind Rectifiers, Bharat Rasayan
This edition of ‘Heard On The Street’ provides you with buzzing action on SBI, Sterlite Tech, GAIL, Mankind Pharma, Exide, Godrej Properties, Laxmi Dental, Hind Rectifiers, and Bharat Rasayan.
NDTV Profit India has been tracking the action in the top dealing rooms of India’s financial capital, and this edition of ‘Heard On The Street’ provides you with buzzing action on stocks like SBI, Sterlite Tech, GAIL, Mankind Pharma, Exide, Godrej Properties, Laxmi Dental, Hind Rectifiers, and Bharat Rasayan.
Heard On The Street provides readers with what well-informed investors, especially HNIs, FIIs, DIIs, and mutual funds, are buying and selling in the stock market. It also tracks the latest unconfirmed/unverified chatter around stocks and/or sectors.
NDTV Profit picked up the following cues from the dealing room chatter during trade:
SBI
Dealers indicate there are buy flows on institutional desks as the stock is now available below the QIP price. SBI had recently raised close to Rs 25000 crore at a price of Rs 817.
Sterlite Tech
There are buy flows on large high-net-worth individuals led by the strong Q1 order book commentary.
GAIL
Dealers indicate there are sell flows on high-net-worth individual desks in anticipation of a potential cut in volume guidance.
Mankind Pharma & Exide
There are sell flows on the institutional desk in trade today. Dealers are expecting weak Q1 earnings.
Godrej Properties
The stock has been under pressure in anticipation of a block deal soon. One of the foreign investors who had put in money during the QIP will look to exit.
Laxmi Dental, Bharat Rasayan, and Hind Rectifiers
Dealers indicate there are buy flows on high-net-worth individuals and the PMS desk.
Disclaimer: The mentioned stocks capture NDTV Profit's dealing room channel checks during trading hours. The information provided is for informational purposes. However, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, or suitability of the information. This content does not constitute financial, investment, or trading advice and should not be construed as a recommendation to buy, sell, or hold any securities.
